Research programme: infectious disease vaccines - PaxVax
Alternative Names: Dengue vaccine - PaxVax; Human papillomavirus infections vaccine - PaxVax; Influenza virus infections vaccine - PaxVax; Malaria vaccine - PaxVax; Poliomyelitis vaccine - PaxVax; Rabies vaccine - PaxVax; Shigella vaccine - PaxVax; Tuberculosis vaccine -PaxVax; Zika virus vaccine - PaxVaxLatest Information Update: 28 Apr 2020
At a glance
- Originator PaxVax
- Class Bacterial vaccines; DNA vaccines; Parasitic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dengue; Human papillomavirus infections; Influenza virus infections; Malaria; Poliomyelitis; Rabies; Shigella infections; Tuberculosis; Zika virus infection
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for research development in Zika-virus-infection(Prevention) in USA
- 04 Oct 2018 PaxVax has been acquired by Emergent BioSolutions
- 28 Aug 2018 No recent reports of development identified for research development in Dengue(Prevention) in USA (PO)
Development Overview
Introduction
PaxVax (a subsidiary of Emergent BioSolutions) has a research programme focussed on developing oral vaccines for various infectious diseases, including seasonal influenza, poliomyelitis (commonly known as polio), malaria, tuberculosis, shigella, human papilloma virus (HPV) infections, dengue, rabies and Zika virus infections. The company has indicated that development is at the early stage in the US.
PaxVax has built a proprietary technology platform based on adenovirus serotype 4 (Ad4), which enables the rapid development of oral vaccines that can target any protein antigen. With this new technology, the company is able to meet the World Health Organization's "ideal vaccine" criteria. Such vaccines must be shown to be safe and effective, suitable for single-dose oral administration, rapid-onset and long-lasting immunity, no need for refrigeration, be affordable and available to billions.
In July 2014, the company announced that it is in process of acquiring assets for the development of travel vaccine against hepatitis A [1] .
As at July 2016, no recent reports of development had been identified for research development in Human-papillomavirus-infections (Prevention) in USA (PO), research development in Influenza-virus-infections (Prevention) in USA (PO), research development in Malaria (Prevention) in USA (PO), research development in Poliomyelitis (Prevention) in USA (PO), research development in Shigella-infections (Prevention) in USA (PO), research development in Tuberculosis (Prevention) in USA (PO).
As at August 2018, no recent reports of development had been identified for research development in Dengue (Prevention) in USA (PO), research development in Rabies (Prevention) in USA (PO).
In October 2018, PaxVax was acquired by Emergent BioSolutions [2] .
As at April 2020, no recent reports of development had been identified for research development in Zika-virus-infection (Prevention) in USA.
Company Agreements
In September 2016, LEUKOCARE granted access to PaxVax for utilisation of two product specific formulations based on it's proprietary SPS® formulation technology platform for the clinical development and subsequent commercialization of one of PaxVax's undisclosed live adenovirus-based vaccine candidate. Under the terms of the agreement, LEUKOCARE will receive milestone payments and annual license fees during development and undisclosed royalties on net sales after commercialisation of the vaccine [3] .
Key Development Milestones
In September 2016, PaxVax announced intention to initiate clinical development of yet undisclosed adeno-associated live viral vaccine candidate [3] .
PaxVax announced in February 2016 that it intends to initiate preclinical studies for its DNA vaccine candidate for Zika virus infections in the first half of 2016.
Drug Properties & Chemical Synopsis
- Route of administration PO
- Formulation unspecified
- Class Bacterial vaccines, DNA vaccines, Parasitic vaccines, Viral vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07A (Bacterial Vaccines)
J07A-N (Tuberculosis vaccines)
J07B-B (Influenza vaccines)
J07B-F (Poliomyelitis vaccines)
J07B-G (Rabies vaccines)
J07B-M (Papillomavirus vaccines)
J07B-X (Other viral vaccines)
P01B (Antimalarials)
V (Various)
-
EPhMRA code
J7A9 (Other specified single component)
J7C (All Other Vaccines)
J7E1 (Influenza vaccines)
P1D (Anti-Malarials)
V (Various)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Dengue | - | Prevention | No development reported (Research) | USA | PO / unspecified | PaxVax | 28 Aug 2018 |
| Human papillomavirus infections | - | Prevention | No development reported (Research) | USA | PO / unspecified | PaxVax | 16 Jul 2016 |
| Influenza virus infections | - | Prevention | No development reported (Research) | USA | PO / unspecified | PaxVax | 16 Jul 2016 |
| Malaria | - | Prevention | No development reported (Research) | USA | PO / unspecified | PaxVax | 16 Jul 2016 |
| Poliomyelitis | - | Prevention | No development reported (Research) | USA | PO / unspecified | PaxVax | 16 Jul 2016 |
| Rabies | - | Prevention | No development reported (Research) | USA | PO / unspecified | PaxVax | 28 Aug 2018 |
| Shigella infections | - | Prevention | No development reported (Research) | USA | PO / unspecified | PaxVax | 16 Jul 2016 |
| Tuberculosis | - | Prevention | No development reported (Research) | USA | PO / unspecified | PaxVax | 16 Jul 2016 |
| Zika virus infection | - | Prevention | No development reported (Research) | USA | unspecified / unspecified | PaxVax | 28 Apr 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| PaxVax | Originator | USA |
| PaxVax | Owner | USA |
| LEUKOCARE | Technology Provider | Germany |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Apr 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Zika-virus-infection(Prevention) in USA Updated 28 Apr 2020 |
| 04 Oct 2018 | Company Involvement | PaxVax has been acquired by Emergent BioSolutions Updated 11 Oct 2018 |
| 28 Aug 2018 | Phase Change - No development reported | No recent reports of development identified for research development in Dengue(Prevention) in USA (PO) Updated 28 Aug 2018 |
| 28 Aug 2018 | Phase Change - No development reported | No recent reports of development identified for research development in Rabies(Prevention) in USA (PO) Updated 28 Aug 2018 |
| 13 Sep 2016 | Licensing Status | PaxVax in-licenses SPS® formulation technology platform from LEUKOCARE [3] Updated 15 Sep 2016 |
| 16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for research development in Human-papillomavirus-infections(Prevention) in USA (PO) Updated 16 Jul 2016 |
| 16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for research development in Influenza-virus-infections(Prevention) in USA (PO) Updated 16 Jul 2016 |
| 16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for research development in Malaria(Prevention) in USA (PO) Updated 16 Jul 2016 |
| 16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for research development in Poliomyelitis(Prevention) in USA (PO) Updated 16 Jul 2016 |
| 16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for research development in Shigella-infections(Prevention) in USA (PO) Updated 16 Jul 2016 |
| 16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for research development in Tuberculosis(Prevention) in USA (PO) Updated 16 Jul 2016 |
| 30 Mar 2016 | Phase Change | Early research in Zika virus infection (Prevention) in USA (unspecified route) Updated 01 Apr 2016 |
| 28 Jul 2014 | Phase Change | Early research in Dengue (Prevention) in USA (PO), prior to July 2014 Updated 07 Aug 2014 |
| 28 Jul 2014 | Phase Change | Early research in Rabies (Prevention) in USA (PO), prior to July 2014 Updated 07 Aug 2014 |
| 19 Mar 2012 | Phase Change | Early research in Human papillomavirus infections (Prevention) in USA (PO) Updated 22 Mar 2012 |
| 19 Mar 2012 | Phase Change | Early research in Influenza virus infections (Prevention) in USA (PO) Updated 22 Mar 2012 |
| 19 Mar 2012 | Phase Change | Early research in Malaria (Prevention) in USA (PO) Updated 22 Mar 2012 |
| 19 Mar 2012 | Phase Change | Early research in Poliomyelitis (Prevention) in USA (PO) Updated 22 Mar 2012 |
| 19 Mar 2012 | Phase Change | Early research in Shigella infections (Prevention) in USA (PO) Updated 22 Mar 2012 |
| 19 Mar 2012 | Phase Change | Early research in Tuberculosis (Prevention) in USA (PO) Updated 22 Mar 2012 |
References
-
PaxVax Acquires the FDA-Approved Typhoid Vaccine Vivotif.
Media Release -
Emergent BioSolutions Completes Acquisition of Specialty Vaccines Company PaxVax.
Media Release -
LEUKOCARE Grants License to US Vaccine Company PaxVax.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG